DH Stock Recent News

Investors interested in Medical Info Systems stocks are likely familiar with Definitive Healthcare Corp. (DH) and Privia Health (PRVA). But which of these two stocks offers value investors a better bang for their buck right now?

Definitive Healthcare (DH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Definitive Healthcare Corp. (NASDAQ:DH ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Matthew Ruderman - Investor Relations Jason Krantz - Founder, Executive Chairman and Interim Chief Executive Officer Rick Booth - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Jared Haase - William Blair Matt Shea - Needham & Company Anne Samuel - JPMorgan David Grossman - Stifel Stephanie Davis - Barclays Operator Welcome to Definitive Healthcare's Q1 2024 Earnings Call. Our host for today's call is Jason Krantz.

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.06 per share a year ago.

Definitive Healthcare Corp. (DH) Q4 2023 Earnings Call Transcript

FRAMINGHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Strengthening fundamentals: Definitive Healthcare shows steady revenue growth at 10% and expanding adjusted EBITDA margins. CRPO growth is slowing to a controlled rate and stabilizing, which indicates the end of client churn that took place over past 2 years. Valuation outlook: Fair price potential around $9.0, signaling a 25% upside from current $7.18.

Definitive Healthcare Corp. (DH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

FRAMINGHAM, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2023, on Thursday, November 2, 2023 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.